Skip to main content
Advertising

Originally published February 22, 2013 at 2:02 AM | Page modified February 22, 2013 at 7:02 AM

  • Share:
             
  • Comments (0)
  • Print

Blaze Bioscience raises $8.5M

The Seattle company’s Tumor Paint technology attaches a fluorescing “beacon” to a molecule that targets solid tumors, with the goal of highlighting cancer cells so they can be completely removed.

By Seattle Times business staff

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

Blaze Bioscience, a Seattle biotechnology company, said it has completed an $8.5 million financing and will use the money for early clinical trials of a product for visualizing cancer tumors during surgery.

The company’s Tumor Paint technology attaches a fluorescing “beacon” to a molecule that targets solid tumors; the goal is to highlight cancer cells so they can be completely removed.

Blaze, a spin-off using discoveries at the Fred Hutchinson Cancer Research Center, has now attracted $9.8 million since its founding in 2010.

News where, when and how you want it

Email Icon

Relive the magic

Relive the magic

Shop for unique souvenirs highlighting great sports moments in Seattle history.

Advertising

Advertising

NDN Video

Advertising